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carla.giordano@unipa.itAbstractObjective: Diabetes mellitus (DM) is one of the most frequent complications of Cushing’s syndrome (CS). The aim of this study
was to define the changes in insulin sensitivity and/or secretion in relation to glucose tolerance categories in newly
diagnosed CS patients.
Design: Cross-sectional study on 140 patients with CS.
Methods: A total of 113 women (80 with pituitary disease and 33 with adrenal disease, aged 41.7G15.7 years) and 27 men
(19 with pituitary disease and eight with adrenal disease, aged 38.1G20.01 years) at diagnosis were divided according to
glucose tolerance into normal glucose tolerance (CS/NGT), impaired fasting glucose and/or impaired glucose tolerance
(CS/prediabetes), and diabetes (CS/DM) groups.
Results: Seventy-one patients had CS/NGT (49.3%), 26 (18.5%) had CS/prediabetes and 43 (30.8%) had CS/DM. Significant
increasing trends in the prevalence of family history of diabetes (P!0.001), metabolic syndrome (P!0.001), age (P!0.001)
and waist circumference (PZ0.043) and decreasing trends in HOMA-b (P!0.001) and oral disposition index (DIo) (P!0.002)
were observed among the groups. No significant trends in fasting insulin levels, area under the curve for insulin (AUCINS),
Matsuda index of insulin sensitivity (ISI-Matsuda) and visceral adiposity index were detected.
Conclusions: Impairment of glucose tolerance is characterized by the inability of b-cells to adequately compensate for insulin
resistance through increased insulin secretion. Age, genetic predisposition and lifestyle, in combination with the duration
and degree of hypercortisolism, strongly contribute to the impairment of glucose tolerance in patients with a natural history
of CS. A careful phenotypic evaluation of glucose tolerance defects in patients with CS proves useful for the identification of
those at a high risk of metabolic complications.European Journal of
Endocrinology
(2014) 170, 311–319IntroductionCushing’s syndrome (CS) results from chronic exposure to
glucocorticoid (GC) excess and is characterized by high
mortality, mainly due to cardiovascular complications,
such as myocardial failure, cerebrovascular disease and
thromboembolism (1, 2). In a recent cohort study, Dekkers
et al. (3) have shown that CS patients with a long-term
increased risk of myocardial infarction require adequate
monitoring and single-risk factor management.
Diabetes mellitus (DM) is one of the most frequent
complications of CS, and its prevalence is considered torange from 20 to 50%, although it may actually be
underestimated (4). Indeed, the prevalence of glucose
tolerance defects increases up to 70% when impaired
fasting glycaemia (IFG) and impaired glucose tolerance
(IGT) are included (5).
Nevertheless, the American Diabetes Association
(ADA) continues to define DM in CS as a ‘specific type of
diabetes secondary to endocrinopathy’, although some
authors judge it as a classical form of type 2 diabetes (6, 7).
Indeed, DM in CS occurs as a consequence of insulin
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Clinical Study C Giordano and others Diabetes in Cushing’s syndrome 170 :2 312resistance and impaired insulin secretion induced by GC
excess (8). Insulin resistance is due to the effects of GCs on
the liver, skeletal muscle and adipose tissue. In particular,
in the skeletal muscle, GC excess has major effects on
glucose metabolism via interference at several steps in the
insulin signalling cascade, resulting in reduced glucose
uptake and glycogen synthesis, and on protein metab-
olism, resulting in proteolysis (7, 8). GC excess also leads
to increased lipolysis. The consequent elevation of amino
acid and free fatty acid levels contributes to further
impairment of insulin signalling and favours hepatic
gluconeogenesis (4). Moreover, GC excess induces a
significant redistribution of adipose tissue from the
subcutaneous to the visceral region and also impairment
of secretion of adipocytokines such as TNFa (TNF) and IL6
and a decrease in adiponectin levels with an increase
in leptin levels (9, 10, 11, 12). Furthermore, it determines
b-cell dysfunction because of reduced insulin sensitivity
and direct b-cell function impairment, through genomic
actions that lead to decreased insulin exocytosis and b-cell
apoptosis, which may be further negatively influenced by
the treatment undergone (8, 9, 10, 11, 12, 13, 14).
This study aimed to define the changes in insulin
secretion and/or sensitivity in a large population of newly
diagnosed CS patients according to glucose tolerance and
to evaluate whether these changes are influenced by
hormonal, metabolic and clinical parameters.Subjects and methods
Patients
We retrospectively revised data collected from 140
consecutive patients with active CS (pituitary and adrenal
dependent), newly diagnosed, and recruited at the
Endocrinology Units of the Universities of Palermo and
Naples between 2000 and 2012.
Data were collected for 113 women (80 with pituitary
disease and 33 with adrenal disease, aged 41.67G15.7
years) and 27 men (19 with pituitary disease and eight
with adrenal disease, aged 38.07G20.01 years).
The diagnosis of CS was based, according to inter-
national criteria, on high daily urinary free cortisol (UFC)
levels (at least three samples), absent cortisol suppression
after a low-dose dexamethasone test (O1.8 mg/dl) and lack
of cortisol rhythm (midnight cortisol levels O7.5 mg/dl);
in addition, the diagnosis of Cushing’s disease was based
on the presence of normal or high plasma adrenocortico-
trophic hormone (ACTH) levels and adequate cortisol
suppression after a high-dose dexamethasone testwww.eje-online.org(O80%), evidence of pituitary adenoma at RMN and
results of inferior petrosal sinus sampling, when required
(15). Instrumental examinations were carried out for
diagnosis definition.
Exclusion criteria were subclinical CS, adrenal or
pituitary cancer, and recurrent CS. No women taking
oestrogens and/or progesterone as contraceptives or
postmenopausal hormones in replacement therapy
were included.
Seven CS patients with IFG were treated with only diet
and one with metformin; 13 patients with IGT were
treated with diet and four with metformin; one patient
with IGFCIGT was treated with metformin; and
12 diabetic patients were treated with diet, 18 with
metformin, and one with sulphonylurea. To avoid an
effect on insulin sensitivity and secretion indexes, all the
diabetic patients treated with oral hypoglycaemic agents
stopped taking them 2 days before the evaluation, while
12 patients treated with insulin stopped using bedtime
insulin the day before the metabolic evaluation.
This study was approved by the Institutional Review
Boards at the Faculty of Medicine of the University of
Palermo and Naples. At the time of hospitalization, all the
patients signed informed consent for the scientific use of
their data. The participants remained anonymous during
the database analysis.Study design
This is a retrospective, cross-sectional study. All the patients
underwent complete clinical and metabolic evaluation as
good clinical practice during diagnosis. The patients were
subdivided into three groups: normal glucose tolerance
(NGT), prediabetes (with IFG, IGT or both) and diabetes
(known or newly diagnosed by oral glucose tolerance test
(OGTT)). BMI, systolic and diastolic blood pressure,
measured according to international criteria (16), waist
circumference (WC), measured at the midpoint between
the lower rib and the iliac crest, and waist/hip ratio (WHR)
were evaluated. After an overnight fast, lipid (total
cholesterol, HDL-C and LDL-C, and triglycerides), HbA1c,
glycaemia and serum insulin profiles were evaluated.
A complete evaluation of the pituitary–adrenal axis,
8-, 16- and 24-h ACTH and cortisol levels, UFC levels as a
mean of three samples from 24-h urine collection, and
serum cortisol levels after a low-dose dexamethasone
suppression test (1 mg) was carried out. OGTT, performed
by measuring plasma blood glucose and insulin levels
every 30 min for 2 h after a 75-g oral glucose load, was
carried out in 66 patients.
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Clinical Study C Giordano and others Diabetes in Cushing’s syndrome 170 :2 313Insulin sensitivity was estimated indirectly using basal
insulin and glucose values to calculate the homeostatic
model of insulin resistance (HOMA2-IR) (glycaemia
(mmol/l)!insulinaemia (mU/ml)/22.5) and using glucose
and insulin values obtained during the OGTT to calculate
the Matsuda index of insulin sensitivity (ISI-Matsuda)
(10 000/glucose (mg/dl)!insulin (mU/ml)!glucose
mean!insulin mean) (17, 18). A composite measure of
b-cell function relative to insulin sensitivity, assessed by
the oral disposition index (DIo), was calculated as
(DInsulin0K30/DGlucose0K30)!(1/fasting insulin). The tra-
pezoidal method was used for the calculation of the area
under the curve for insulin (AUC2-h insulin) and area under
the curve for glucose (AUC2-h glucose) (19). The HOMA-bwas
calculated as 360!(insulin)/((glucose)K63) % (glucose in
mg/dl) (17).
The visceral adiposity index (VAI) was calculated
according to gender, where TG is the triglyceride level
expressed in mmol/l and HDL is the HDL-C level expressed
in mmol/l:
i) VAIZ(WC/39.68C(1.88!BMI))!(TG/1.03)!
(1.31/HDL) for males;
ii) VAIZ(WC/36.58C(1.89!BMI))!(TG/0.81)!
(1.52/HDL) (20) for females.
The metabolic syndrome (MS) was diagnosed according
to the NCEP ATP III criteria, whereas DM and prediabetes
were diagnosed according to the ADA criteria (6, 21).Hormone and biochemical assays
Serum insulin, glucose and lipid levels were measured by
ELISA (DRG Instruments GmbH, Marburg, Germany). The
normal insulin range was 5–19 UI/ml. LDL-C levels were
measured using the Friedewald formula (total cholesterolK
(HDLC(TG/5)). HbA1c levels were determined by HPLC
with an ion-exchange resin (HA8121, Hi-AutoA1c,
Menarini, Florence, Italy). UFC levels were measured by
RIA (Diagnostic System Laboratories, Inc., Roche Diagnos-
tics GmbH, Mannheim , Germany) with a normal range of
36–137 mg/24 h. ACTH levels were measured using ELISA
(DRG Instruments GmBH) with a normal range of
7.6–66.1 pg/ml. Serum cortisol levels were measured using
RIA (Diagnostic Systems Laboratories, Inc.) with a reference
range of 22.8–217 ng/ml. The conversion factors for the
International System (SI) were as follows: glucose mg/dl vs
mmol/l: 0.0555; insulin mUI/ml vs pmol/l: 6.945;
total cholesterol and HDL-C mg/dl vs mmol/l: 0.0259;
triglycerides mg/dl vs mmol/l: 0.0113; and cortisol ng/ml vs
nmol/l: 3.180.Statistical analysis
The Statistical Packages for Social Science SPSS version 17
(SPSS, Inc.) was used for data analysis. The normality of
quantitative variables was tested with the Shapiro–Wilk
test. Baseline characteristics are presented as meansGS.D.
for continuous variables; rates and proportions were
calculated for categorical data. Differences between two
groups were detected using unpaired Student’s t-test for
continuous variables (after testing for equality of variance:
Levene’s test) and the c2 test and Fisher’s exact test (when
appropriate) for categorical variables. The ANOVA trend
analysis for quantitative variables and c2 for trend for
categorical variables were carried out for the three groups:
CS/NGT, CS/prediabetes and CS/DM. A P value!0.05 was
considered to be statistically significant.Results
Metabolic and clinical parameters according to gender
The clinical, phenotypic and biochemical features of all
the patients grouped according to gender are listed out in
Tables 1, 2 and 3. No differences were found between men
and women, except for BMI (F vs M: 31.35G6.03 vs
28.78G5.52 kg/m2; PZ0.039) and VAI (F vs M: 2.82G1.51
vs 1.46G0.75; P!0.001).Metabolic and clinical parameters according to
glucose tolerance
Of the 140 patients with CS, 71 were classified as having
CS/NGT (49.3%), 26 (18.5%) CS/prediabetes and 43 CS/DM
(30.8%) (Table 4). Significant increasing trends were
observed in age (CS/NGTZ35.05G16.34; CS/prediabetes
Z41.27G12.97; CS/DMZ50.58G14.64 years; P!0.001)
and WC (CS/NGTZ100.85G14.77; CS/prediabetesZ
106.28G17.49; CS/DMZ106.76G16.00 cm; PZ0.043).
A non-significant trend was observed in BMI (CS/NGTZ
30.00G5.07; CS/prediabetesZ31.18 kg/m2 G6.08;
CS/DMZ32.07G7.19; PZ0.072) (Table 4).
In addition, an increasing trend was observed in the
familial history of DM (CS/NGTZ29.6%; CS/prediabetesZ
46.2%; CS/DMZ65.1%; P!0.001) and cardiovascular
disease (CS/NGTZ54.9%; CS/prediabetesZ76.9%;
CS/DMZ81.4%; PZ0.002), MS (CS/NGTZ39.4%; CS/
prediabetesZ76.9%; CS/DMZ93%; P!0.001) and
hypertension (CS/NGTZ67.6%; CS/prediabetesZ76.9%;
CS/DMZ86%; P!0.026) (Table 4).www.eje-online.org
Table 1 Clinical and phenotypic features of all the 140 CS patients at diagnosis grouped according to gender.
Data is presented as meanGS.D. or as n(%).
Women (nZ113) Men (nZ27) Total (nZ140) P
Age (years) 41.67G15.7 38.07G20.01 40.98G16.61 0.314
BMI (kg/m2) 31.35G6.03 28.78G5.52 30.86G6.01 0.039
WC 104.04G15.53 102.16G17.33 103.68G15.83 0.609
WHR 1.01G0.09 1.03G0.05 1.01G0.09 0.242
Family history of
Diabetes 48 (42.5) 13 (48.1) 61 (43.6) 0.593
Cardiovascular disease 75 (66.4) 19 (70.4) 94 (74.1) 0.691
Dyslipidaemia 30 (26.5) 9 (33.3) 39 (27.9) 0.480
Smoking 40 (35.4) 14 (51.9) 54 (38.6) 0.115
Pituitary disease 80 (78.8) 19 (70.4) 99 (70.7) 0.965
Adrenal disease 33 (29.2) 8 (29.6) 41 (29.3) 0.965
Autoimmune thyroid disease 13 (11.5) 1 (0.4) 14 (10) 0.607
Multinodular goitre 14 (12.4) 2 (7.4) 16 (11.4) 0.737
Muscle hypotrophy 46 (40.7) 9 (33.3) 55 (39.3) 0.481
Moon face 58 (51.3) 12 (44.4) 70 (50) 0.520
Facial plethora 59 (52.2) 13 (48.1) 72 (51.4) 0.704
Buffalo hump 44 (38.9) 6 (22.2) 50 (35.7) 0.103
Purple striae 45 (39.8) 13 (48.1) 58 (41.4) 0.430
Ecchymosis 25 (22.1) 7 (25.9) 32 (22.9) 0.673
Coronary heart disease 19 (16.8) 4 (14.8) 23 (16.4) 1
Coagulopathy 7 (6.2) 3 (11.1) 10 (7.2) 0.406
Peripheral vascular disease 5 (4.4) 2 (7.4) 7 (5) 0.620
Cerebral vascular disease 10 (8.8) 2 (7.4) 12 (8.6) 1
Depression 27 (23.9) 5 (18.5) 32 (22.9) 0.550
Osteoporosis 25 (22.1) 7 (25.9) 32 (22.9) 0.673
Fractures 10 (8.8) 5 (18.5) 15 (10.7) 0.144
Vertebral collapse 11 (9.7) 2 (7.4) 13 (9.3) 1
Arthropathy 39 (34.5) 8 (29.6) 47 (33.6) 0.629
Hepatic steatosis 42 (57.5) 9 (69.2) 51 (59.3) 0.547
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Clinical Study C Giordano and others Diabetes in Cushing’s syndrome 170 :2 314Nodifferenceswere foundinvenous thrombosis, fasting
insulin levels, total HDL-C and LDL-C levels, triglyceride
levels, AUCINS, ISI-Matsuda and VAI (Table 4). A decreasing
trend was observed in HOMA-b (CS/NGTZ170.65G43.07;
CS/prediabetesZ163.46G77.52; CS/DMZ87.11G76.94;
P!0.001) and DIo (CS/NGTZ3.04G3.68; CS/prediabetes
Z0.87G1.12; CS/DMZ0.70G1.07; P!0.001) (Table 4).
As expected, a significant increasing trend was observed
in fasting glucose levels (CS/NGTZ4.77G0.64; CS/
prediabetesZ5.43G0.97; CS/DMZ7.79G2.68 mmol/l;
P!0.001), AUC2-h glucose (CS/NGTZ14 756G3038; CS/
prediabetesZ17 314G4890; CS/DMZ24 707G8882;
PZ0.005) and HbA1c levels (CS/NGTZ34.97G3.4; CS/
prediabetesZ39.89G5.1; CS/DMZ54.20G12.4 mmol/mol;
P!0.001) (Table 4).Hormonal parameters according to glucose tolerance
Circadian rhythms for ACTH and cortisol, UFC and cortisol
after the administration of 1 mg dexamethasone did not
differ significantly among the three groups (Table 4).www.eje-online.orgDiscussion
The results of this study indicate that, in agreement with
the literature data, the prevalence of CS is high in women
(80.71%). The sexual dimorphism of CS in women has
already been documented (22). To date, it is estimated that
Cushing’s disease occurs five times more frequently in
women than in men (23). Women with CS have a higher
BMI than men, with similar values of WC, because in CS
the gender differences in fat distribution are lost precisely
because the adipose tissue is redistributed from the
peripheral to the visceral region, leading to the well-
known phenotype characterized by gynoid obesity,
independently of sex (24, 25, 26, 27). In our study, CS
women had a significantly higher VAI, consequent on the
influence of GC excess on visceral adipose dysfunction.
The VAI is a gender-specific index, which was modelled on
healthy men and women (20, 28). The increase in the VAI,
specifically observed in CS women, confirms the loss of
cardiovascular protection in relation to gender, and CS
women even developed worse visceral adipose dysfunc-
tion (indirectly expressed by the VAI) compared with men,
Table 2 Hormonal parameters of all the 140 CS patients at diagnosis grouped according to gender. Data is presented
as meanGS.D.
Women (nZ113) Men (nZ27) Total (nZ140) P
8-h ACTH (pg/ml) 55.13G44.27 58.79G46.89 55.85G44.64 0.715
16-h ACTH (pg/ml) 45.48G36.2 44.33G34.12 45.42G35.69 0.969
24-h ACTH (pg/ml) 48.14G27.42 41.76G35.2 46.26G29.79 0.475
8-h Cortisol (nmol/l) 817.26G225.78 791.82G279.8 814.08G235.32 0.626
16-h Cortisol (nmol/l) 747.30G232.14 610.56G241.68 728.22G238.5 0.142
24-h Cortisol (nmol/l) 629.64G313.73 508.8G225.78 594.66G292.56 0.115
Urinary free cortisol (m/24 h) 393.39G348.45 518.92G457.98 416.87G372.76 0.122
Cortisol after an overnight
dexamethasone suppression
test (nmol/l)
295.74G248.04 397.5G384.78 314.82G276.66 0.344
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acromegaly, prolactinoma and diabetes (28, 29, 30, 31).
However, despite this evidence, the VAI in CS has a strong
application limit. The reason for this is that it is an
indicator of early cardiometabolic risk and an important
diagnostic tool in all borderline conditions in which overt
MS is not present (32). Indeed, in our cohort of CS
patients, 62.9% had overt MS, and so the VAI cannot beTable 3 Metabolic parameters of all the 140 CS patients at d
as n(%) or as meanGS.D.
Women (nZ113)
Metabolic syndromea 75 (66.4)
Diabetes or fasting glucose
R5.6 mmol/l
42 (37)
High blood pressure 84 (74.3)
High triglycerides 38 (33.6)
Low HDL-C 72 (63.7)
Increased WC 94 (83.2)
Hypercholesterolaemia 49 (43.4)
Impaired fasting glucose (IFG) 6 (5.3)
Impaired glucose tolerance (IGT) 14 (12.4)
IFGCIGT 0
Diabetes mellitus 36 (31.9)
Total cholesterol (mmol/l) 5.19G0.93
HDL-C (mmol/l) 1.27G0.33
LDL-C (mmol/l) 3.11G0.87
Triglycerides (mmol/l) 1.58G0.60
Fasting glucose (mmol/l) 5.79G2.08
Fasting insulin (UI/ml) 13.16G6.28
HOMA2-IR 2.00G0.95
HOMA-b 142.99G69.9
AUC2-h glucose
b 18 168G7180
AUC2-h insulin
b 9627G5721
ISI-Matsudab 4.16G3.48
Oral disposition index (DIo)b 1.88G3.07
HbA1c (%) 6.24G1.13
HbA1c (mmol/mol) 45.0G12.4
VAI 2.76G1.41
aAccording to the Adult Treatment Panel (ATP) III criteria.
bIn a subgroup of 66 patients without known diabetes.considered a specific index for these patients. This is
explained by the fact that three of the variables making up
the VAI (WC, TG and HDL) are dichotomically expressed
in the criteria of MS. In a recent letter, the applicative
limits of VAI in single patients have been pointed out and
it has been recommended that for proper application in an
individual patient or in small sample studies the appli-
cation of the VAI is not suggested, above all in theiagnosis grouped according to gender. Data is presented
Men (nZ27) Total (nZ140) P
13 (48.1) 88 (62.9) 0.078
10 (8) 52 (46) 0.017
21 (67.8) 105 (75) 0.711
9 (33.3) 47 (33.6) 0.977
5 (18.5) 77 (55) !0.001
20 (74.1) 114 (81.4) 0.279
12 (44.4) 61 (43.6) 0.919
2 (7.4) 8 (5.7) 0.651
3 (11.1) 17 (12.1) 1
1 (3.7) 1 (0.7) 0.193
7 (25.9) 43 (30.7) 0.548
4.79G0.88 5.11G0.93 0.049
1.35G0.36 1.29G0.34 0.243
2.74G0.79 3.04G0.86 0.037
1.32G0.57 1.53G0.60 0.059
5.97G2.12 5.82G2.08 0.753
14.73G7.53 13.46G6.54 0.407
2.21G1.10 2.04G0.98 0.432
146.44G88.13 143.66G72.38 0.935
17 822G5703 18 095G6854 0.987
9602G6696 9622G5891 0.974
3.53G1.83 4.02G3.19 0.615
1.43G1.27 1.78G2.78 0.913
6.5G1.13 6.29G1.13 0.357
48.0G12.4 45.0G12.4 0.357
1.43G1.27 2.51G1.40 !0.001
www.eje-online.org
Table 4 Clinical and biochemical features of all the 140 CS patients divided into three groups (normal glucose tolerance (CS/NGT),
prediabetes (CS/prediabetes) and diabetes (CS/DM)). Data is presented as meanGS.D. or as n(%).
CS/NGT (nZ71) CS/prediabetes (nZ26) CS/DM (nZ43) P
Age (years) 35.05G16.34 41.27G12.97 50.58G14.64 !0.001
BMI (kg/m2) 30.00G5.07 31.18G6.08 32.07G7.19 0.072
WC 100.85G14.77 106.28G17.49 106.76G16.00 0.043
WHR 1.01G0.09 1.02G0.09 1.01G0.08 0.900
Male 14 (19.7) 6 (23.1) 7 (16.3) 0.696
Female 57 (80.3) 20 (76.9) 36 (83.7) 0.696
Family history of
Diabetes 21 (29.6) 12 (46.2) 28 (65.1) !0.001
Cardiovascular disease 39 (54.9) 20 (76.9) 35 (81.4) 0.002
Dyslipidaemia 18 (25.4) 10 (38.5) 11 (25.6) 0.863
Smoking 23 (32.4) 10 (38.5) 21 (48.8) 0.082
Pituitary disease 48 (67.6) 21 (80.8) 30 (69.8) 0.704
Adrenal disease 23 (32.4) 5 (19.2) 13 (30.2) 0.704
Metabolic syndromea 28 (39.4) 20 (76.9) 40 (93) !0.001
Hypertension 48 (67.6) 20 (76.9) 37 (86) 0.026
Venous thrombosis 7 (5) 5 (4.4) 2 (7.4) 0.620
Hormonal parameters
8-h ACTH (pg/ml) 51.11G42.87 65.85G34.47 57.86G52.00 0.365
16-h ACTH (pg/ml) 40.90G36.18 55.58G35.24 45.58G35.47 0.530
24-h ACTH (pg/ml) 41.27G31.00 52.66G20.32 51.00G31.50 0.209
8-h Cortisol (nmol/l) 782.28G209.88 817.26G235.32 858.6G270.3 0.102
16-h Cortisol (nmol/l) 734.58G190.8 721.86G228.96 718.68G340.26 0.815
24-h Cortisol (nmol/l) 556.5G238.5 607.38G295.74 645.54G365.7 0.249
Urinary free cortisol (m/24 h) 436.25G334.20 376.82G322.03 409.54G457.89 0.668
Cortisol after an overnight
dexamethasone suppression
test (nmol/l)
302.1G273.48 333.9G263.94 321.18G292.56 0.783
Metabolic parameters
Total cholesterol (mmol/l) 4.95G0.87 5.60G1.08 5.09G0.86 0.258
HDL-C (mmol/l) 1.31G0.35 1.32G0.37 1.22G0.29 0.237
LDL-C (mmol/l) 2.94G0.83 3.36G0.99 3.00G0.80 0.586
Triglycerides (mmol/l) 1.47G0.71 1.74G0.97 1.64G0.7 0.215
Fasting glucose (mmol/l) 4.77G0.64 5.43G0.97 7.79G2.68 !0.001
Fasting insulin (UI/ml) 13.54G5.23 17.06G8.05 10.97G6.39 0.079
HOMA2-IR 1.97G0.79 2.57G1.19 1.83G1.05 0.671
HOMA-b 170.65G43.07 163.46G77.52 87.11G76.94 !0.001
AUC2-h glucose
b 14 756G3038 17 314G4890 24 707G8882 0.005
AUC2-h insulin
b 10 615G6259 10 398G5769 7104G4854 0.066
ISI-Matsudab 4.25G1.93 3.35G1.95 4.33G5.38 0.947
Oral disposition index (DIo)b 3.04G3.68 0.87G1.12 0.70G1.07 0.002
HbA1c (%) 5.35G0.31 5.80G0.47 7.11G1.13 !0.001
HbA1c (mmol/mol) 34.97G3.4 39.89G5.1 54.20G12.4 !0.001
VAI 2.36G1.44 2.43G1.11 2.82G1.46 0.102
aAccording to the Adult Treatment Panel (ATP) III criteria.
bIn a subgroup of 66 patients without known diabetes.
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hypertriglyceridaemia and/or fibrate use (33).
The results of our study indicate that DM patients are
significantly older, have a higher prevalence of family
history of DM and exhibit a marked deterioration of
insulin secretion indexes.
The familial history of DM appears to predispose CS
patients to worse metabolic derangement. It is worth
noting that DM is a polygenic disease, and among all the
genetic factors described, the presence of relatives affectedwww.eje-online.orgby the disease remains one of the most important
determinants for predicting the onset of disease (34).
The role of age in the development of type 2 diabetes
is unanimously recognized, and these findings were
confirmed in our cohort, i.e. CS/DM patients are older
than CS/NGT and CS/prediabetes patients.
A condition of insulin resistance has been reported in
hypercortisolism (35). Surprisingly, neither ISI-Matsuda
nor HOMA-IR was significantly affected in CS/DM patients
in comparison with that in the other CS patients. By
Figure 1
Diabetes in CS is due to complex and heterogeneous pathophysio-
logical mechanisms linked only in part to insulin resistance.
(A) Patients with normal glucose tolerance. Age, genetic predis-
position and lifestyle in association with visceral adipose dysfunction
determine an early onset of insulin resistance and trigger reduction
of insulin secretion. CS onset, through its specific factors, favours the
impairment of glucose tolerance and the development of IFG/IGT
(latent diabetes is triggered). (B) Patients with IFG/IGT. Age, genetic
predisposition and lifestyle in association with visceral adipose
dysfunction determine a worsening of insulin resistance and a
significant reduction of insulin secretion. CS onset, through its
specific factors, favours the impairmentof glucose toleranceand the
development of diabetes (latent diabetes is revealed). (C) Patients
with diabetes. Age, genetic predisposition and lifestyle in associ-
ation with visceral adipose dysfunction determine a significant
progression of insulin resistance and a strong reduction of insulin
secretion. CS onset, through its specific factors, together with the
DM-specific ones, completely eliminates glucose tolerance, deter-
mining the decompensation of diabetes (diabetes mellitus is overt).
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insulin resistance (DIo), but not of absolute insulin
secretion (AUCINS), was observed in CS/DM patients in
addition to the reduction of HOMA-b (3, 12). Indeed, the
DIo, which expresses the ability of b-cells to adequately
compensate for insulin resistance through increased
insulin secretion, has been shown to predict the
development of diabetes in adults (19). Therefore, the
DIo could be used for evaluating diabetes risk linked to
the CS condition.
These data show that patients with CS/DM have a
strong insulin secretion defect without a worsening of
insulin sensitivity in comparison with CS/NGT and
CS/prediabetes patients. Therefore, diabetes in CS could
probably be strongly influenced by b-cell defect that would
occur after a long period of insulin resistance. This
observation is not new, even if the data available are on
mice or on patients with exogenous hypercortisolism (36).
However, these data need to be investigated further.
Recently, many studies have been conducted on the
usefulness of evaluating the hypothalamus–pituitary–
adrenal axis in patients with DM. To date, this evaluation
is not recommended (37, 38). Moreover, there are no data
that can define any differences between patients with
classic DM and those with CS and DM.
From the data obtained in our study, we can
hypothesize that a time-dependent prodromal period,
influencing both CS and DM, progresses together with
other variables that can play a distinct role in the
determination of diabetes in CS, such as the duration of
disease, degree of hypercortisolism and genetic factors.
The first consideration points out that the duration of
disease is a parameter that is not always determinable
in CS because the onset of CS is subtle and is usually
diagnosed some time after the real onset of the disease. On
the other hand, the degree of hypercortisolism may be
variable: obviously marked hypercortisolism should exert
an effect different from that of slight hypercortisolism. In
this light, recently, it has been suggested that GC action
may be influenced by GC receptor (GR (NR3C1)) poly-
morphisms (39). Some GR polymorphisms have been
demonstrated to impair GC sensitivity and can be
associated with altered metabolic profiles. In particular,
N363S, BCL1 and ER22/EK are associated with diabetes,
hypertension and dyslipidaemia, while A3669G GR
polymorphism seems to be protective in CS (39).
A further confirmation of the complex and hetero-
geneous variables implicated in the development of
diabetes in CS is emerging from the different effects of
pasireotide on glucose tolerance in patients with CS: somewww.eje-online.org
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NGT. This difference is most probably due to the
interplay between pasireotide b-cell effects and genetic/
environmental factors (40). Moreover, the complexity of
the pathogenesis of diabetes in CS could also be supported
by the evidence that in a large number of patients with CS,
DM persists also after definitive treatment when total
resolution of CS has been achieved (41).
Based on the above, we could suggest that in CS
diabetes is due to the action of non-modifiable risk factors,
such as age and genetic predisposition, and modifiable risk
factors, such as lifestyle, which are independent of
hypercortisolism. When CS becomes overt through some
specific factors, such as the exact duration of hypercorti-
solism, GR polymorphisms and degree of hypercortiso-
lism, it contributes to the impairment of glucose
tolerance. Therefore, in the presence of the above-
mentioned characteristics, if a patient has NGT, s/he will
develop prediabetes or diabetes; if a patient has predia-
betes, s/he will develop DM; and if a patient is diabetic,
s/he will exhibit a worsening of glycaemic control with
decompensated diabetes (Fig. 1).
Clearly, obesity and MS are additional factors that are
associated with chronic inflammation contributing to the
further development of insulin resistance and progression
to diabetes. Local hyperactivity of GCs in abdominal
adipose tissue contributes to the pathogenesis of MS and
ongoing development of DM, steps that may vary in a CS
patient in relation to different mechanisms arising in the
history of the disease (27, 42). Therefore, careful phenotypic
evaluation of glucose tolerance defects in patients with CS is
necessary, using, if possible, accurate examinations to verify
insulin secretion and sensitivity, before beginning medical
treatment for CS, which can further impair glucose
tolerance. In addition, this phenotypic evaluation could
be essential above all for the identification of the best
therapeutic management of diabetes in CS.
In conclusion, the results of this study suggest that
DM is not a simple consequence of hypercortisolism and
that both genetic predisposition for DM and hypercorti-
solism, working together, exert dangerous effects on
glucose metabolism. However, increased insulin resistance
and decreased insulin secretion entities may be extremely
different in a single CS patient during the course of
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